TXMD TherapeuticsMD, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 25743 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY33.9%
TTM net income YoY-59.6%
TTM EPS YoY-50.0%
Revenue 3-yr CAGR24.3%
Net income 3-yr CAGR-87.9%
Margins
Gross margin—
Operating margin-95.3%
Net margin3.3%
FCF margin—
EBITDA margin-85.1%
Returns
ROE0.4%
ROA0.3%
ROIC (approx.)-19.0%
Asset turnover0.10x
Leverage & solvency
Liabilities / assets27.2%
Debt / equity0.00x
Current ratio3.32x
Interest coverage—
Cash quality & payout
Operating cash flow / net income27.59x
Accruals ratio-8.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.26M | $869,000 | $724,000 | $893,000 | $784,000 | $952,000 | $393,000 | $667,000 |
| SG&A expense | $1.64M | $1.58M | $1.35M | $2.29M | $1.52M | $1.55M | $1.49M | -$140,000 |
| Operating income | -$479,000 | -$816,000 | -$723,000 | -$1.55M | -$862,000 | -$695,000 | -$1.28M | $700,000 |
| Interest expense | — | — | — | $1,000 | $3,000 | $2,000 | $2,000 | $1,500 |
| Pretax income | $501,000 | $164,000 | $103,000 | -$580,000 | $50,000 | $545,000 | -$668,000 | $83,000 |
| Income tax | — | — | — | — | $0 | $0 | -$32,000 | — |
| Net income | $491,000 | $155,000 | $95,000 | -$619,000 | $152,000 | $551,000 | -$653,000 | $252,000 |
| EBITDA | -$382,000 | -$721,000 | -$629,000 | -$1.46M | -$766,000 | -$599,000 | -$1.19M | $800,000 |
| EPS (basic) | 0.04 | 0.01 | 0.01 | — | 0.01 | 0.05 | -0.06 | — |
| EPS (diluted) | 0.04 | 0.01 | 0.01 | — | 0.01 | 0.05 | -0.06 | — |
| Weighted avg. shares (diluted) | 11.64M | 11.64M | 11,640 | — | 11.57M | 11.57M | 11,552 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $10.45M | $9.19M | $8.42M | $7.48M | $7.12M | $6.07M | $5.75M | $5.06M |
| Current assets | $17.42M | $16.12M | $15.26M | $14.45M | $14.50M | $13.46M | $12.51M | $12.26M |
| Intangibles | $3.46M | $3.56M | $3.67M | $3.76M | $3.91M | $4.04M | $4.14M | $4.32M |
| Total assets | $37.93M | $37.53M | $37.58M | $37.66M | $38.67M | $38.50M | $38.24M | $38.82M |
| Current liabilities | $5.25M | $5.00M | $4.91M | $4.79M | $4.95M | $4.66M | $4.74M | $5.17M |
| Total liabilities | $10.31M | $10.40M | $10.61M | $10.78M | $11.23M | $11.21M | $11.50M | $11.45M |
| Shareholders' equity | $27.62M | $27.13M | $26.97M | $26.88M | $27.44M | $27.29M | $26.74M | $27.37M |
| Shares outstanding | 11.57M | 11.57M | 11.57M | 11.57M | 11.57M | 11.57M | 11.57M | 11.53M |
| Cash flow statement | ||||||||
| Operating cash flow | $1.27M | $779,000 | $944,000 | $375,000 | $999,000 | $381,000 | $699,000 | $17,000 |
| Depreciation & amortization | $97,000 | $95,000 | $94,000 | $97,000 | $96,000 | $96,000 | $95,000 | $100,000 |
| Stock-based compensation | $1,000 | $4,000 | $2,000 | $51,000 | $0 | $1,000 | $23,000 | $24,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.